Hyku Biosciences
Precise covalent targeting of disease-causing proteins and developing small molecule therapeutics with novel mechanisms of action to transform conventional treatment paradigms.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | $56.0m | Seed | |
| Total Funding | 000k | ||
Related Content
Hyku Biosciences is at the forefront of developing small molecule therapeutics designed to inactivate proteins that drive disease progression. Operating in the biopharmaceutical sector, Hyku focuses on pioneering covalent medicines that target histidine, tyrosine, and lysine binding pockets within disease-causing proteins. This approach offers superior selectivity and drug properties by irreversibly blocking the activity of these targets, expanding beyond the traditional cysteine targeting methods.
The company serves patients suffering from diseases driven by these proteins, aiming to transform conventional treatment paradigms. Hyku's business model revolves around research and development of these novel therapeutics, with revenue generated through partnerships, licensing agreements, and potentially direct sales of approved drugs.
Hyku Biosciences is committed to innovation, collaboration, and respect within its diverse team, all united by the mission to improve patient lives.
Keywords: covalent medicines, small molecule therapeutics, disease progression, protein inactivation, histidine targeting, tyrosine targeting, lysine targeting, biopharmaceutical, drug development, patient-centric.